Recursion Pharm stock had its Relative Strength (RS) Rating upgraded from 78 to 84 Tuesday.
IBD's unique RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the last 52 weeks matches up against that of all other stocks.
Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an RS Rating of above 80 in the early stages of their moves.
Hone Your Stock=Picking Skills By Focing On These Factors
Is Recursion Pharm Stock A Buy?
Recursion Pharm stock recently reclaimed its 50-day moving average. Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the biotech stock is able to form a consolidation and break out.
The biotech company showed 0% EPS growth in its most recent report, while sales growth came in at 14%.
Recursion Pharm stock holds the No. -1 rank among its peers in the Medical-Biomed/Biotech industry group.
